News

New investors include GE, BioMed Ventures and Henri Termeer, former Chairman and CEO of Genzyme Corporation. According to the company, the financing will be used to continue the

Cimzia is a PEGylated anti-TNF (Tumor Necrosis Factor), having high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. The data suggested that disease activity response

DEB025 belongs to a new class of drugs called cyclophilin inhibitors and offers an effective treatment option across HCV genotypes, with a high barrier to resistance. The 12-week

PatientKeeper’s clinical applications provides a physician-friendly interface and allows voluntary physician adoption of healthcare IT required for meaningful use compliance. Conway will install PatientKeeper’s CPOE (Computerised Physician Order

As per the deal, Astra Zeneca lab will choose between 250 anticancer drugs that will be produced in Algeria, bernama.com.my reported. The agreement will be signed by end

The technology, HyACT, is said to improve the delivery of chemotherapy drugs to site of tumours, including HA-irinotecan, which combines with Pfizer’s Camptosar for the treatment of colon

According to the company, in January 2012, the facility for Cyprotex’s US operations will be increased from 4,400 sq ft to 8,200 sq ft in order to meet

The trial was intended to test the safety and toxicity of CV9201, besides its ability to induce antigen-specific humoral and cellular immune responses in cancer patients. The trial

Realize, a randomised, double-blind, placebo-controlled Phase 3 trial compared the efficacy, safety and tolerability of telaprevir in 662 patients with chronic genotype-1 HCV who failed prior treatment with